Dianthus Therapeutics expects to initiate a Phase 3 trial for claseprubart in gMG in mid-2026, with results in H2 2028. The company's existing cash is sufficient to fund operations into 2028.
Bullish
Dianthus Therapeutics achieved positive Phase 2 results for claseprubart in gMG, advanced its Phase 3 trial for CIDP with an early "GO," and expanded its pipeline with DNTH212, initiating Phase 1.
Bearish
Dianthus Therapeutics reported increased net losses in 2025, faces substantial capital requirements, and is exposed to supply chain risks from its sole manufacturer, alongside intense market competition.